← All trials
NCT04375605
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- May 31, 2028
- Completion date
- Aug 31, 2028
- First posted
- May 5, 2020
- Last posted
- May 5, 2020
- Enrollment
- 340
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MannheimLead sponsor
- Deutsche Krebshilfe e.V.Collaborator
- University of MannheimReponsible party - principal investigator
- University of MannheimOverall official - principal investigator
- IKF Klinische Krebsforschung GmbH am Krankenhaus NordwestCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.